환자의 신약 접근성 강화 정책 제안

키워드

참고문헌 (50)

1. 이태진, "의약품 보험 급여 및 가격 결정과 경제성 평가의 활용", 예방의학회지, 41(2), pp.69~73 (2008), 대한예방의학회
2. Yoo SL, "Improving patient access to new drugs in South Korea : Evaluation of the national drug formulary system", Int J Environ Res Public Health, 16(2), pp.288~ (2019)
3. Ha D, "A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea", Clin Ther, 33(7), pp.926~932 (2011)
4. Hogerzeil HV, "The concept of essential medicines : lessons for rich countries", BMJ, 329(7475), pp.1169~1172 (2004)
5. Wiedenmayer K, "Managing Pharmaceuticals in International Health", pp.19~31 (2004), Birkhäuser
6. "Monitoring the building blocks of health systems: A handbook of indicators and their measurement strategies"[URL]
7. Kwon HY, "Availability and affordability of drugs with a conditional approval by the European Medicines Agency; comparison of Korea with other countries and the implications", Front Pharmacol, 9, pp.938~ (2018)
8. Frank R. Lichtenberg, "The Health Impact of, and access to, New Drugs in Korea", East Asian Economic Review, 24(2), pp.127~164 (2020), 대외경제정책연구원[DOI]
9. Kim ES, "The effect of policies for improving the access to new medicine: A retrospective analysis in 2007-2016", Ph.D, pp.2016
10. "The United States vs. Other Countries: Availability of New Medicines Varies"[URL]
11. "The United States vs. Other Countries: Availability of Cancer Medicines Varies"[URL]
12. 김유진, "의약품 접근성 향상을 위한 방안 고찰", 한국임상약학회지, 28(1), pp.40~50 (2018), 한국임상약학회[DOI]
13. Andersson F, "The Drug Lag Issue : The debate seen from an international perspective", Int J Health Serv, 22(1), pp.53~72 (1992)
14. Okabayashi S, "Drug lag for inflammatory bowel disease treatments in the East and West", Inflamm Intest Dis, 3(1), pp.25~31 (2018)
15. Lee SW, "Notable differences in drug lag between Korea and Japan of new drugs between 2009 and 2017", Ther Innov Regul Sci, 54(2), pp.418~423 (2020)
16. "Step 4: FDA Drug Review"[URL]
17. "CDER Approval Times for Priority and Standard NDAs and BLAs Calendar Years 1993 – 2015"[URL]
18. "Increase user fee, planning to recruit '87+a' drug approval review personnel"[URL]
19. "Review report on the 2020 budget plan revenue and expenditure under the jurisdiction of the Ministry of Food and Drug Safety"[URL]
20. "2018 Drug Approval Report"[URL]
21. "A Study on the Improvement of the Legal System for the Development of Advanced Biopharmaceuticals Regulatory System"[URL]
22. 최혜영, "한국의 신약 허가기간에 대한 조사 연구(2011~2017년)", 약 학 회 지, 64(1), pp.47~53 (2020), 대한약학회[DOI]
23. "Future Prospect of Pharmaceuticals and Medium to Long-Term Strategy of Health Policy and Governance"[URL]
24. Cameron D, "On what basis are medical costeffectiveness thresholds set? Clashing opinions and an absence of data : a systematic review", Glob Health Action, 11(1), pp.1447828~ (2018)
25. Kaitin KI, "Deconstructing the drug development process : the new face of innovation", Clin Pharmacol Ther, 87(3), pp.356~361 (2010)
26. "Criteria for detailed evaluation of drugs subject to negotiation, such as new drugs (amendment)"[URL]
27. "Health insurance coverage for high-priced drugs such as targeted cancer drugs is expanded"[URL]
28. "The new drug registration system, ‘RSA’, why is it not working?"[URL]
29. Campbell SM, "Defining quality of care", Soc Sci Med, 51(11), pp.1611~1625 (2000)
30. "Pre-announcement of new drug evaluation regulations to enhance patient access to rare disease medicines, etc"[URL]
31. "Results of the Evaluation Committee on the Listing of Drugs"[URL]
32. "Opinion inquiry for “Criteria for detailed evaluation of drugs subject to negotiation, such as new drugs”"[URL]
33. "A study of post-list management for indispensable drugs of Korean National Health Insurance"[URL]
34. "Standards on Designation, Implementation, etc. of Differential Coverage"[URL]
35. "Notice No. 2020-181 (2020.8.24) of “Drug reimbursement list and reimbursed price cap table”"[URL]
36. "No. 2020-107,108, The Second Recruitment Notice for Medical Product Sector Reviewers (new, alternative)"[URL]
37. "Ministry of Food and Drug Safety and its affiliated organizations"[URL]
38. "Prescription Drug User Fee Amendments"[URL]
39. "Regulations on fees for licensing medicines, etc"[URL]
40. "Fees payable to the European Medicines Agency"[URL]
41. "Fees for regulatory review and face-to-face consultation"[URL]
42. 김수진, "희귀질환 약제, 항암제 별도 기금 도입에 대한 약제급여 결정 전문가와 이해관계자 시각", 한국임상약학회지, 30(3), pp.177~184 (2020), 한국임상약학회[DOI]
43. "Moon Jae-in care (Health Insurance Coverage Enhancement, Moon Jae-in Care Plus)"[URL]
44. "Status and Future Plans for Strengthening Health Insurance Coverage"[URL]
45. "A Study on the Improvement of Access to Medicines for Four Major Severe Diseases - Focusing on the Financing of Rare Disease Therapy and Anti-cancer Drugs"[URL]
46. "Generics 360-Generic drugs in Canada, 2018"[URL]
47. Yoon YK, "Trends of antibiotic consumption in Korea according to national reimbursement data (2008-2012): A population-based epidemiologic study", Medicine (Baltimore), 94(46), pp.e2100~ (2015)
48. "Announcement of a pilot project to re-evaluate the appropriateness of health insurance policies"[URL]
49. "Disclosure of the results of deliberation by the 6th Drug Reimbursement Evaluation Committee in 2020"[URL]
50. Holtorf A-P, "External reference pricing for pharmaceuticals-a survey and literature review to describe best practices for countries with expanding healthcare coverage", Value Health Reg Issues, 19, pp.122~131 (2019)

관련 논문AI추천